Retinal degeneration in a rodent model of Smith-Lemli-Opitz syndrome: Electrophysiologic, biochemical, and morphologic features

Archives of Ophthalmology

Volumn 122, Issue 8, 2004, Pages 1190-1200

  Fliesler, Steven J ^a   Peachey, Neal S ^b,c   Richards, Michael J ^a   Nagel, Barbara A ^a   Vaughan, Dana K ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN OSHKOSH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(2 CHLOROBENZYLAMINOMETHYL)CYCLOHEXANE; 3BETA HYDROXYSTEROL DELTA7 REDUCTASE; 7 DEHYDROCHOLESTEROL; CHOLESTEROL; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAM; HISTOLOGY; NONHUMAN; PHOTOTRANSDUCTION; PRIORITY JOURNAL; RAT; RETINA CONE; RETINA DEGENERATION; RETINA ROD; SMITH LEMLI OPITZ SYNDROME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DARK ADAPTATION; DEHYDROCHOLESTEROLS; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; FEMALE; PIGMENT EPITHELIUM OF EYE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL DEGENERATION; SMITH-LEMLI-OPITZ SYNDROME; TRANS-1,4-BIS(2-CHLOROBENZAMINOMETHYL)CYCLOHEXANE DIHYDROCHLORIDE;

EID: 3543086891     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.8.1190     Document Type: Article

References (81)

1. Smith JD, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. J Pediatr. 1964;64:210-217.
2. Kelley RI. Inborn errors of cholesterol biosynthesis. Adv Pediatr. 2000;47:1-53.
3. Porter FD. Human malformation syndromes due to inborn errors of cholesterol synthesis. Curr Opin Pediatr. 2003;15:607-613.
4. Herman GE. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Mol Genet. 2003;12(suppl 1):R75-R88.
5. Battaile KP, Battaile BC, Merkens LS, Maslen CL, Steiner RD. Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome. Mol Genet Metab. 2001;72:67-71.
6. Irons M, Elias ER, Salen G, Tin S, Batta AK. Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome [letter]. Lancet. 1993;341:1414.
7. Tint GS, Irons M, Elias ER, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med. 1994;330:107-113.
8. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI. Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet. 1997;68:263-269.
9. 7- dehydrocholesterol reductase mutations in patients with the Smith-Lemli-Opitz (RSH) syndrome. Hum Mol Genet 2000;9:1385-1391.
10. Salen G, Shefer S, Batta AK, et al. Abnormal cholesterol biosynthesis in the Smith-Lemli-Opitz syndrome. J Lipid Res. 1996;37:1169-1180.
11. Tint GS, Batta AK, Xu G, et al. The Smith-Lemli-Opitz syndrome: a potentially fatal birth defect caused by a block in the last enzymatic step in cholesterol biosynthesis. Subcell Biochem. 1997;28:117-144.
12. Waterham HR, Wanders RJ. Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. Biochim Biophys Acta. 2000; 1529:340-356.
13. Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, et al. Mutational spectrum in the Δ7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet. 2000;66:402-412.
14. Nowaczyk MJ, Nakamura LM, Waye JS. DHCR7 and Smith-Lemli-Opitz syndrome. Clin Invest Med. 2001;24:311-317.
15. Jira PE, Waterham HR, Wanders RJ, Smeitink JA, Sengers RC, Wevers RA. Smith-Lemli-Opitz syndrome and the DHCR7 gene. Ann Hum Genet. 2003;67(pt 3): 269-280.
16. Finley SC, Finley WH, Monsky DB. Cataracts in a girl with features of the Smith-Lemli-Opitz syndrome. J Pediatr. 1969;75:706-707.
17. Cotlier E, Rice P. Cataracts in the Smith-Lemli-Opitz syndrome. Am J Ophthalmol. 1971;72:955-959.
18. Gold JD, Pfafffenbach DD. Ocular abnormalities in the Smith-Lemli-Opitz syndrome. J Pediatr Ophthalmol. 1975;12:228-234.
19. Gracia R, Nieto JA, Nistal M, et al. Aniridia associated with gonadoblastoma in Smith-Lemli-Opitz syndrome (author's transl) [in Spanish]. An Esp Pediatr. 1976; 9:19-24.
20. Fierro M, Martinez AJ, Harbison JW, Hay SH. Smith-Lemli-Opitz syndrome: neuropathological and ophthalmological observations. Dev Med Child Neurol. 1977; 19:57-62.
21. Harbin RL, Katz JI, Frias JL, Rabinowicz IM, Kaufman HE. Sclerocornea associated with the Smith-Lemli-Opitz syndrome. Am J Ophthalmol. 1977;84:72-73.
22. Freedman RA, Baum JL. Postlenticular membrane associated with Smith-Lemli-Opitz syndrome. Am J Ophthalmol. 1979;87:675-677.
23. Kretzer FL, Hittner HM, Mehta RS. Ocular manifestations of the Smith-Lemli-Opitz syndrome. Arch Ophthalmol. 1981;99:2000-2006.
24. Bardelli AM, Lasorella G, Barberi L, Vanni M. Ocular manifestations in Kniest syndrome, Smith-Lemli-Opitz syndrome, Hallermann-Streiff-Francois syndrome, Rubinstein-Taybi syndrome and median cleft face syndrome. Ophthalmic Paediatr Genet. 1985;6:343-347.
25. Belmont JW, Hawkins E, Hejtmancik JF, Greenberg F. Two cases of severe lethal Smith-Lemli-Opitz syndrome. Am J Med Genet. 1987;26:65-67.
26. Curry CJ, Carey JC, Holland JS, et al. Smith-Lemli-Opitz syndrome-type II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality. Am J Med Genet. 1987;26:45-57.
27. Elias ER, Irons MB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet. 1997;68:305-310.
28. Atchaneeyasakul LO, Linck LM, Connor WE, Weleber RG, Steiner RD. Eye findings in 8 children and a spontaneously aborted fetus with RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet. 1998;80:501-505.
29. Kolf-Clauw M, Chevy F, Wolf C, Siliart B, Citadelle D, Roux C. Inhibition of 7-dehydrocholesterol reductase by the teratogen AY9944: a rat model for Smith-Lemli-Opitz syndrome. Teratology. 1996;54:115-125.
30. Kolf-Clauw M, Chevy F, Ponsart C. Abnormal cholesterol biosynthesis as in Smith-Lemli-Opitz syndrome disrupts normal skeletal development in the rat. J Lab Clin Med. 1998;131:222-227.
31. Chambers CM, McLean MP, Ness GC. Smith-Lemli-Opitz syndrome produced in rats with AY 9944 treated by intravenous injection of lipoprotein cholesterol. Am J Med Genet. 1997;68:322-327.
32. Xu G, Salen G, Shefer S, et al. Treatment of the cholesterol biosynthetic defect in Smith-Lemli-Opitz syndrome reproduced in rats by BM 15.766. Gastroenterology. 1995;109:1301-1307.
33. 7-reductase inhibitors: comparison to levels in humans with Smith-Lemli-Opitz syndrome. J Lipid Res. 1996;37:1325-1333.
34. Kolf-Clauw M, Chevy F, Siliart B, Wolf C, Mulliez N, Roux C. Cholesterol biosynthesis inhibited by BM 15.766 induces holoprosencephaly in the rat. Teratology. 1997;56:188-200.
35. O'Brien WT, Xu G, Tint GS, Salen G, Servatius RJ. Blocking cholesterol synthesis impairs acquisition of the classically conditioned eyeblink response. Integr Physiol Behav Sci. 2000;35:120-131.
36. Fitzky BU, Moebius FF, Asaoka H, et al. 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest. 2001;108:905-915.
37. Wassif CA, Zhu P, Kratz L, et al. Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome. Hum Mol Genet. 2001;10:555-564.
38. Fliesler SJ, Richards MJ, Miller CY, Peachey NS. Marked alteration of sterol metabolism and composition without compromising retinal development or function. Invest Ophthalmol Vis Sci. 1999;40:1792-1801.
39. Flieser SJ, Richards MJ, Peachey NS, Buchan B, Vaughan OK, Organisciak DT. Potentiation of retinal light damage in an animal model of Smith-Lemli-Opitz syndrome [ARVO abstract]. Invest Ophthalmol Vis Sci. 2001;42:S627. Abstract 3373.
40. Elias ER, Hansen RM, Irons M, Quinn NB, Fulton AB. Rod photoreceptor responses in children with Smith-Lemli-Opitz syndrome. Arch Ophthalmol. 2003; 121:1738-1743.
41. Lamb TD, Pugh EN Jr. A quantitative account of the activation steps involved in phototransduction in amphibian photoreceptors. J Physiol. 1992;449:719-758.
42. Pugh EN Jr, Lamb TD. Amplification and kinetics of the activation steps in phototransduction. Biochim Biophys Acta. 1993;1141:111-149.
43. Breton ME, Schueller AW, Lamb TD, Pugh EN Jr. Analysis of ERG a-wave amplification and kinetics in terms of the G-protein cascade of phototransduction. Invest Ophthalmol Vis Sci. 1994;35:295-309.
44. Hood DC, Birch DG. Rod phototransduction in retinitis pigmentosa: estimation and interpretation of parameters derived from the rod a-wave. Invest Ophthalmol Vis Sci. 1994;35:2948-2961.
45. Goto Y, Peachey NS, Ziroli NE, et al. Rod phototransduction in transgenic mice expressing a mutant opsin gene. J Opt Soc Am A. 1996;13:577-585.
46. Lyubarsky AL, Pugh EN Jr. Recovery phase of the murine rod photoresponse reconstructed from electroretinographic recordings. J Neurosci. 1996;16:563-571.
47. Cheng T, Peachey NS, Li S, Goto Y, Cao Y, Naash MI. The effect of peripherin/rds haploinsufficiency on rod and cone photoreceptors. J Neurosci. 1997;17: 8118-8128.
48. Fliesler SJ, Richards MJ, Miller C, Peachey NS, Cenedella RJ. Retinal structure and function in an animal model that replicates the biochemical hallmarks of desmosterolosis. Neurochem Res. 2000;25:685-694.
49. Pittler SJ, Fliesler, SJ, Fisher P, Keller RK, Rapp LM. In vivo requirement of protein prenylation for maintenance of retinal cytoarchitecture and photoreceptor structure. J Cell Biol. 1995;130:1-9.
50. Fliesler SJ, Richards MJ, Miller CY, Cenedella RJ. Cholesterol synthesis in the vertebrate retina: effects of U18666A on rat retinal structure, photoreceptor membrane assembly, and sterol metabolism and composition. Lipids. 2000;35:289-296.
51. Vaughan DK, Nemke JL, Fliesler SJ, Darrow RM, Organisciak DT. Evidence for a circadian rhythm of light damage susceptibility in rats. Photochem Photobiol. 2002;75:547-553.
52. Vaughan DK, Coulibaly SF, Darrow RM, Organisciak DT. A morphometric study of light damage in transgenic rat models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2003;44:848-855.
53. Xu L, Ball SL, Alexander KR, Peachey NS. Pharmacological analysis of the rat cone ERG. Vis Neurosci. 2003;20:297-306.
54. 7-reductase, on serum and tissue lipids in the rat. J Lipid Res. 1968;9:587-595.
55. Dvornik D, Kraml M, Dubuc J, Givner M, Gaudry R. A novel mode of inhibition of cholesterol biosynthesis [letter]. J Am Chem Soc. 1963;85:3309.
56. Givner ML, Dvornik D. Agents affecting lipid metabolism, XV: biochemical studies with the cholesterol biosynthesis inhibitor AY-9944 in young and mature rats. Biochem Pharmacol. 1965;14:611-619.
57. LaVail MM. Outer segment disc shedding and phagocytosis in the outer retina. Trans Ophthalmol Soc U K. 1983;103(pt 4):397-404.
58. Nguyen-Legros J, Hicks D. Renewal of photoreceptor outer segments and their phagocytosis by the retinal pigment epithelium. Int Rev Cytol. 2000;196:245-313.
59. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22:79-131.
60. Stubbs CD. Membrane fluidity: structure and dynamics of membrane lipids. Essays Biochem. 1983;19:1-39.
61. Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta. 1985;822: 267-287.
62. Kofuji P, Ceelen P, Zahs KR, Surbeck LW, Lester HA, Newman EA. Genetic inactivation of an inwardly rectifying potassium channel (Kir4.1 subunit) in mice: phenotypic impact in retina. J Neurosci. 2000;20:5733-5740.
63. Hood DC, Birch DG. A computational model of the amplitude and implicit time of the b-wave of the human ERG. Vis Neurosci. 1992;8:107-126.
64. Fliesler SJ. Effects of cholesterol biosynthesis inhibitors on retinal development, structure, and function. In: Fliesier SJ, ed. Sterols and Oxysterols: Chemistry, Biology and Pathobiology. Kerala, India: Research Signpost; 2002:77-109.
65. Boulton M, Rozanowska M, Rozanowski B. Retinal photodamage. J Photochem Photobiol. B. 2001;64:144-161.
66. Organisciak DT, Winkler BS. Retinal light damage: practical and theoretical considerations. Prog Ret Eye Res. 1994;13:1-29.
67. Reme CE, Grimm C, Hafezi F, Iseli HP, Wenzel A. Why study rod cell death in retinal degenerations and how? Doc Ophthalmol. 2003;106:25-29.
68. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr. 1995;62(suppl 6): 1448S-1461S.
69. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration [online serial]. Mol Vis. 1999;5:32-42. Available at: http://www.molvis.org/molvis/v5/p32. Accessed March 22, 2004.
70. Rao NA, Wu GS. Free radical mediated photoreceptor damage in uveitis. Prog Ret Eye Res. 2000;19:41-68.
71. Vaughan DK, Richards MJ, Fliesler SJ. DMTU protects against light-induced retinal degeneration in an animal model of Smith-Lemli-Opitz syndrome. In: Annual Meeting Abstract Search and Program Planner [book on CD-ROM]. Rockville, Md: Association for Research in Vision & Ophthalmology; April 1, 2002. Abstract 3729.
72. Richards MJ, Nagel BA, Fliesler SJ. Lipid hydroperoxide formation in an animal model of Smith-Lemli-Opitz syndrome: correlation with retinal degeneration and exposure to constant light. In: Annual Meeting Abstract Search and Program Planner [book on CD-ROM]. Rockville, Md: Association for Research in Vision & Ophthalmology; April 1, 2003. Abstract 3548.
73. De Fabiani E, Caruso D, Cavaleri M, Galli Kienle M, Galli G. Cholesta-5,7,9(11)-trien-3β-ol found in plasma of patients with Smith-Lemli-Opitz syndrome indicates formation of sterol hydroperoxide. J Lipid Res. 1996;37:2280-2287.
74. Gaoua W, Chevy F, Roux C, Wolf C. Oxidized derivatives of 7-dehydrocholesterol induce growth retardation in cultured rat embryos: a model for antenatal growth retardation in the Smith-Lemli-Opitz syndrome. J Lipid Res. 1999;40: 456-463.
75. Sakuragawa N, Sakuragaw M, Kuwabara T, Pentchev PG, Barranger JA, Brady RO. Niemann-Pick disease experimental model: sphingomyelinase reduction induced by AY-9944. Science. 1977;196:317-319.
76. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, Satoyoshi E, Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem (Tokyo). 1985;98:1669-1679.
77. Igarashi M, Suzuki K, Chen SM. Changes in brain hydrolytic enzyme activities in rats treated with cholesterol biosynthesis inhibitor, AY9944. Brain Res. 1975; 90:97-114.
78. Irons M, Elias ER, Abuelo D, et al. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet. 1997;68:311-314.
79. Linck LM, Lin DS, Flavell D, Connor WE, Steiner RD. Cholesterol supplementation with egg yolk increases plasma cholesterol and decreases plasma 7-dehydrocholesterol in Smith-Lemli-Opitz syndrome. Am J Med Genet. 2000;93:360-365.
80. Nwokoro NA, Mulvihill JJ. Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. Am J Med Genet. 1997;68:315-321.
81. Starck L, Lovgren-Sandblom A, Bjorkhem I. Cholesterol treatment forever? the first Scandinavian trial of cholesterol supplementation in the cholesterol-synthesis defect Smith-Lemli-Opitz syndrome. J Intern Med. 2002;252:314-321.